infliximab-qbtx
E850384
Infliximab-qbtx is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biosimilar medicinal product
ⓘ
monoclonal antibody ⓘ tumor necrosis factor alpha inhibitor ⓘ |
| adverseEffect |
abdominal pain
ⓘ
headache ⓘ infusion-related reactions ⓘ nausea ⓘ rash ⓘ upper respiratory tract infection ⓘ |
| belongsToPharmacologicClass |
biologic disease-modifying antirheumatic drug
ⓘ
immunosuppressant ⓘ |
| belongsToRegulatoryCategory | prescription-only medicine ⓘ |
| belongsToTherapeuticArea |
dermatology
ⓘ
gastroenterology ⓘ rheumatology ⓘ |
| contraindication |
moderate to severe heart failure
ⓘ
severe active infection ⓘ |
| effect |
induces and maintains clinical remission in inflammatory bowel disease
ⓘ
reduces signs and symptoms of inflammation ⓘ |
| hasAdministrationPattern | induction and maintenance dosing schedule ⓘ |
| hasATCClass | L04AB02 ⓘ |
| hasEffectOn |
immune system modulation
ⓘ
pro-inflammatory cytokine activity ⓘ |
| hasImmunoglobulinType | IgG1 ⓘ |
| hasMolecularType | chimeric monoclonal antibody ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasTarget | tumor necrosis factor alpha NERFINISHED ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isBiosimilarOf | infliximab NERFINISHED ⓘ |
| isIntendedFor | adult patients ⓘ |
| mayBeUsedIn | pediatric patients for certain indications ⓘ |
| mechanismOfAction |
binds to soluble and transmembrane TNF-alpha
ⓘ
inhibits TNF-alpha mediated inflammatory signaling ⓘ |
| requiresMonitoring |
complete blood count
ⓘ
liver function tests ⓘ signs and symptoms of infection ⓘ |
| requiresScreeningBeforeUse |
hepatitis B virus infection
ⓘ
latent tuberculosis infection ⓘ |
| usedFor |
Crohn’s disease
NERFINISHED
ⓘ
ankylosing spondylitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| warning |
risk of hepatitis B virus reactivation
ⓘ
risk of malignancies including lymphoma ⓘ risk of reactivation of latent tuberculosis ⓘ risk of serious infections ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.